Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-26-006446
Filing Date
2026-02-12
Accepted
2026-02-12 16:30:45
Documents
56
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 629286
2 EX-31.1 ex31-1.htm EX-31.1 13574
3 EX-32.1 ex32-1.htm EX-32.1 7322
  Complete submission text file 0001493152-26-006446.txt   3296914

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE aneb-20251231.xsd EX-101.SCH 27301
5 XBRL CALCULATION FILE aneb-20251231_cal.xml EX-101.CAL 32994
6 XBRL DEFINITION FILE aneb-20251231_def.xml EX-101.DEF 98535
7 XBRL LABEL FILE aneb-20251231_lab.xml EX-101.LAB 252501
8 XBRL PRESENTATION FILE aneb-20251231_pre.xml EX-101.PRE 210632
58 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 357865
Mailing Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734
Business Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

EIN.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-40388 | Film No.: 26626767
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)